What is Lifesci Capital’s Forecast for Immunome Q1 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Stock analysts at Lifesci Capital raised their Q1 2026 earnings per share (EPS) estimates for Immunome in a research report issued to clients and investors on Wednesday, August 6th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings per share of ($0.73) for the quarter, up from their previous forecast of ($0.75). The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2026 earnings at ($0.73) EPS.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.02. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. The firm had revenue of $4.02 million during the quarter, compared to analysts’ expectations of $1.03 million.

Other research analysts have also recently issued reports about the company. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. dropped their target price on Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $21.00 target price on shares of Immunome in a report on Thursday, August 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Immunome Stock Down 0.3%

Shares of NASDAQ:IMNM opened at $9.66 on Monday. Immunome has a 52-week low of $5.15 and a 52-week high of $16.73. The stock has a market cap of $840.81 million, a price-to-earnings ratio of -3.14 and a beta of 1.93. The business has a 50-day moving average price of $9.56 and a 200-day moving average price of $8.90.

Insider Buying and Selling

In other Immunome news, Director Jean Jacques Bienaime acquired 5,000 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were bought at an average cost of $9.38 per share, with a total value of $46,900.00. Following the completion of the acquisition, the director owned 36,415 shares in the company, valued at approximately $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.69% of the stock is currently owned by company insiders.

Institutional Trading of Immunome

A number of institutional investors have recently made changes to their positions in IMNM. JPMorgan Chase & Co. boosted its stake in shares of Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after acquiring an additional 624,045 shares during the last quarter. Wellington Management Group LLP boosted its stake in Immunome by 3.5% during the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after buying an additional 4,874 shares during the last quarter. Geode Capital Management LLC boosted its stake in Immunome by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after buying an additional 21,396 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Immunome by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 26,207 shares of the company’s stock worth $278,000 after buying an additional 8,190 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Immunome by 2,696.5% during the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after buying an additional 304,700 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.